• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Medical Device Market
Medical Device News
Medical Device Stocks
  • Medical Device Market
  • Medical Device News
  • Medical Device Stocks
medical device investing

Medigus and Golden Grand Expand Distribution Arrangement in China

Bryan Mc Govern
Jul. 18, 2017 08:40AM PST
Medical Device Investing

Medigus announced the Chinese exclusive distribution agreement with Golden Grand was expanded to account for the increased interest in the MUSE system in China.

Medigus (NASDAQ:MDGS) announced the Chinese exclusive distribution agreement with Golden Grand was expanded to account for the increased interest in the MUSE system in China.
As quoted in the press release:

The expanded distribution agreement states that Golden Grand has committed to a minimum purchase of $27 million worth of the MUSE™ system and related equipment over the course of five years, from the date of CFDA (China Food and Drug Administration) approval. Golden Grand, a Chinese company specializing in the distribution of medical devices, will now serve as the exclusive distributor for the MUSE™ systems in China. These terms replace the former distribution agreement, which included a minimum purchase of $17 million worth of systems over the course of four years.
“The expansion of our distribution arrangement with Golden Grand confirms our continued commitment to bring the MUSE system to the Chinese market, offering an innovative gastroesophageal reflux disease (GERD) treatment to the Chinese population, which was previously unavailable,” said Chris Rowland, Chief Executive Officer of Medigus. “We are looking forward to our continued work with Golden Grand, and through our work together we believe we can help reduce the unmet treatment need for patients who fall within the gap between drug therapy and invasive surgical procedures.”

Click here to read the full press release.

Source: www.marketwired.com

drug therapy distribution agreement china china food and drug administration gastroesophageal reflux disease medical device investing food and drug administration
The Conversation (0)

Go Deeper

AI Powered
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

Life Science Outlook

Life Science Outlook

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Medical Device Investing Stocks

Cardiex Limited

Cardiex Limited (CDX:AU)
CDX:AU

Cleo Diagnostics

Cleo Diagnostics (COV:AU)
COV:AU

Ocumetics Technology

Ocumetics Technology (OTC:CC)
OTC:CC

Avricore Health

Avricore Health (AVCR:CC)
AVCR:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES